Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
Copyright policy )Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.
- University of Virginia United States
Adult, Male, Clinical Trials as Topic, Influenza A Virus, H3N2 Subtype, Administration, Oral, Adamantane, Body Temperature, Nasal Mucosa, Random Allocation, Rimantadine, Double-Blind Method, Influenza A virus, Influenza, Human, Humans, Female
Adult, Male, Clinical Trials as Topic, Influenza A Virus, H3N2 Subtype, Administration, Oral, Adamantane, Body Temperature, Nasal Mucosa, Random Allocation, Rimantadine, Double-Blind Method, Influenza A virus, Influenza, Human, Humans, Female
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).81 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!